Clinical trials: Malignant Melanoma
Skin Tumors, Melanoma
Skin Cancer Screening Education Study
The overall aim of this population-based screening study is to assess whether the skin cancer screening training of family physicians and dermatologists leads to improved screening outcomes.
- Conditions
- Skin Tumors, Melanoma, Basal Cell Carcinoma, Squamous Cell Carcinoma
- Trial name
- SCSES (NCT02352428)
- Testing
- Skin Cancer Screening Training
- Where
- Canada
- Volunteers
- 113 people, healthy volunteers welcome
- Sponsor
- Association of Dermatological Prevention, Germany
Skin Cancer
Symptom Burden in Patients With Cancer- and Treatment-Related Skin Problems
Objectives: The objective of this study is to develop a valid and reliable measure of the symptom burden experienced by patients with cancer experiencing disease-related skin problems and to delineate this burden over time.
- Trial name
- NCT01193036
- Testing
- Part 1: Interview + Questionnaires, Part 2: Multiple Questionnaires
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- M.D. Anderson Cancer Center
Melanoma
A Pilot Study of Intraoperative Gamma Camera Imaging During Sentinel Node Biopsy for Melanoma
This is a single-institution pilot study seeking preliminary evidence of the usefulness of mobile gamma cameras in patients undergoing sentinel node biopsy for melanoma.
- Trial name
- MEL50 (NCT00912730)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Virginia
Melanoma
PROSECCO: A Phase 2, Single Arm, Neoadjuvant Study Evaluating Combination Cemiplimab, Fianlimab, And Ipilimumab In Patients With Surgically Resectable Melanoma
This is a phase II study testing the safety and preliminary efficacy of triplet ICB in treatment naïve patients with clinical stage III or oligometastatic stage IV melanoma with resectable disease.
- Trial name
- NCT07511036
- Testing
- Cemiplimab, Lpilimumab, Fianlimab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Melanoma
Phase 1 Study of MPC-6827 and Temozolomide in Metastatic Melanoma
This is an open-label, dose finding, multiple-dose study in subjects with metastatic melanoma. Three dose levels of MPC-6827 will be administered with temozolomide to three separate cohorts.
- Trial name
- NCT00609011
- Testing
- MPC-6827 + Temozolomide
- Where
- 5 sites in United States
- Volunteers
- 22 people
- Sponsor
- Myrexis Inc.
Lung Cancer, Adult Soft Tissue Sarcoma
Vaccine Therapy in Treating Patients With Metastatic Cancer
RATIONALE: Vaccines made from a peptide may make the body build an immune response and kill tumor cells. PURPOSE: Randomized phase I trial to study the effectiveness of vaccine therapy in treating patients who have metastatic…
- Conditions
- Lung Cancer, Adult Soft Tissue Sarcoma, Colorectal Cancer, Bone Cancer
- Trial name
- NCT00020267
- Testing
- interleukin-2, MAGE-12 peptide vaccine, Montanide ISA-51
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Non Small Cell Lung Cancer, Advanced Triple Negative Breast Cancer
A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients
This study will look at the safety of the combination of three drugs (CDX-1401, Poly-ICL, and Pembrolizumab) and its effect on decreasing tumors. Pembrolizumab is an experimental cancer drug.
- Conditions
- Non Small Cell Lung Cancer, Advanced Triple Negative Breast Cancer, Small Cell Lung Cancer, Urothelial Cancer
- Trial name
- NCT02661100
- Testing
- Pembrolizumab, CDX-1401, Poly-ICLC
- Sponsor
- Case Comprehensive Cancer Center
Non Small Cell Lung Cancer, Urothelial Carcinoma
Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors
In this phase I first-in-humans-study a vaccine consisting of arginase-1 (ARG1) peptides and the adjuvant Montanide ISA-51 will be tested in ten patients with metastatic solid tumors.
- Conditions
- Non Small Cell Lung Cancer, Urothelial Carcinoma, Malignant Melanoma, Ovarian Cancer
- Trial name
- NCT03689192
- Testing
- ARG1-18,19,20
- Where
- Denmark
- Volunteers
- 13 people
- Sponsor
- Herlev Hospital
Melanoma
The Tolerance,Pharmacokinetic Characteristics,Safety and Efficacy of ScTIL210 in the Treatment of Melanoma
This is an open-lable, single-arm, single-dose escalation and multiple-dose expansion clinical study of cell therapy to observe and evaluate the tolerance, pharmacokinetic characteristics, safety and efficacy of ScTIL210（Super…
- Trial name
- NCT04357509
- Testing
- Super circulating tumor infiltrating lymphocytes(ScTIL)
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Peking University Cancer Hospital & Institute
Melanoma, Survivors
Health Behaviors, Surveillance, Psychosocial Factors, and Family Concerns
The purpose of this study is to examine the health behaviors of melanoma survivors. We want to know about their thoughts and concerns. Melanoma is a type of skin cancer.
- Conditions
- Melanoma, Survivors, Psychological Factors
- Trial name
- NCT00518050
- Testing
- Focus group, Survey
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Melanoma
Safety and Efficacy of an Immune Response Modifier to Treat Inoperable Advanced Melanoma Skin Lesions
Study 1501-852A is a Phase 1 Study with the objective of determining safety and the highest tolerated dose of an immune response modifier cream directly applied to advanced, inoperable, melanoma skin lesions.
- Trial name
- NCT00091689
- Testing
- 852A
- Where
- 2 sites in United States
- Sponsor
- Pfizer
Malignant Melanoma, Carcinoma, Non-Small-Cell Lung
A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement
First-in-human study to assess safety, tolerability, PK, and preliminary activity of PF-07284890 as a single agent and in combination with binimetinib in participants with BRAF V600-mutated advanced solid tumor malignancies with…
- Conditions
- Malignant Melanoma, Carcinoma, Non-Small-Cell Lung, Brain Neoplasms, Primary, Brain Neoplasms
- Trial name
- NCT04543188
- Testing
- PF-07284890, Binimetinib, Midazolam
- Where
- 45 sites in United States, Canada and 1 more
- Volunteers
- 65 people
- Sponsor
- Pfizer
Resectable Mucosal Melanoma
Paclitaxel Polymersomes + Carboplatin + Adebelimab: Neoadjuvant Phase Ⅱ Single-Arm Study for Resectable Mucosal Melanoma
The primary objective of this study is to evaluate the pathological response rate of neoadjuvant therapy with paclitaxel polymersomes for injection combined with carboplatin and adebrelimab in patients with resectable mucosal…
- Trial name
- NCT07336979
- Testing
- Paclitaxel Polymersomes Combined with Carboplatin and Adebelimab, Radical Surgery
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Sun Yat-sen University
Metastatic Melanoma
A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients
The purpose of this study is to test the combination of Ipilimumab and GM-CSF. Both ipilimumab and GM-CSF are intended to work with the body's own immune system to attack melanoma cells in the body.
- Trial name
- NCT02009397
- Testing
- Ipilimumab, GM-CSF
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Louisville
Melanoma
MySmartSkin Online Skin Self-exam Intervention for Melanoma Survivors
This project, mySmartSkin (MSS), includes an innovative Type 1 hybrid effectiveness-implementation trial designed to enhance the effects of MSS and simultaneously assess key implementation outcomes (e.g., cost, adoption) as well…
- Trial name
- NCT05373823
- Testing
- MySmartSkin enhancement, Educational webpage on Skin Self-Examination, Assess implementation outcomes
- Where
- United States
- Volunteers
- 385 people
- Sponsor
- Rutgers, The State University of New Jersey
Solid Tumors
A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
This is an open-label, multicenter Phase 2 study evaluating Navlimetostat (BMS-986504) in participants with advanced and/or metastatic solid tumors that have MTAP deletion.
- Trial name
- NCT07492680
- Testing
- Navlimetostat, Daraxonrasib, Temozolomide
- Where
- 58 sites in United States, Belgium and 11 more
- Volunteers
- 254 people
- Sponsor
- Bristol-Myers Squibb
Cutaneous Melanoma, Melanoma Stage IV
Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma
Clear-Me is a biomarker-driven phase II study that tests whether the combination anti- lymphocyte-activation gene-3 (LAG3)/anti-programmed cell death protein 1(PD-1) inhibition Bristol-Myers Squibb (BMS986213) is superior to…
- Conditions
- Cutaneous Melanoma, Melanoma Stage IV, Mucosal Melanoma
- Trial name
- ClearMe (NCT06319196)
- Testing
- Opdualag, Nivolumab
- Where
- Canada
- Volunteers
- 54 people
- Sponsor
- University Health Network, Toronto
Melanoma, Metastatic Melanoma
NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma
This research study is studying the drugs called NeoVax (a new type of personalized neoantigen vaccine) in combination with CDX-301 and Nivolumab or Pembrolizumab as a possible treatment for melanoma.
- Trial name
- NCT04930783
- Testing
- CDX-301, NEOVAX, Nivolumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Dana-Farber Cancer Institute
Muscle-Invasive Bladder Carcinoma, Gastroesophageal Adenocarcinoma
Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease
This is a phase 1 clinical trial to evaluate the safety, feasibility and immunogenicity of a personalized cancer vaccine strategy in patients with solid tumors and molecular residual disease.
- Conditions
- Muscle-Invasive Bladder Carcinoma, Gastroesophageal Adenocarcinoma, Melanoma, Non-small Cell Lung Cancer
- Trial name
- NCT06529822
- Testing
- Synthetic long peptide personalized cancer vaccine, Poly ICLC, Signatera or Altera testing
- Where
- 3 sites in United States
- Volunteers
- 64 people
- Sponsor
- Washington University School of Medicine
Melanoma Stage I, Melanoma Stage III
Adjuvant Therapy of Skin Melanoma With Alpha Interferon and Naderin
The goal of this clinical trial is to learn if adding alpha interferon to standard treatment works to prevent skin melanoma from coming back after surgery.
- Conditions
- Melanoma Stage I, Melanoma Stage III, Melanoma Stage II, Skin Melanoma
- Trial name
- ATSMAIN (NCT07671495)
- Testing
- Surgical resection, Adjuvant Radiotherapy, interferon alfa
- Volunteers
- 278 people
- Sponsor
- MIPO Clinic
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.